Current Treatment of Alopecia Areata

Maria K. Hordinsky

doi:10.1016/j.jisp.2020.04.004

Current Treatment of Alopecia Areata

Maria K. Hordinsky

Dermatology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The number of alopecia areata (AA) clinical trials with Jak inhibitors of cytoplasmic tyrosine kinases, including Jak1, Jak2, Jak3, and tyrosine-protein kinase has increased significantly since the last Research Summit. This fact means that the conversation about current treatments for AA now also needs to include a discussion of traditionally used off-label therapies as well as evolving therapies as with Jak inhibitors.

Original language	English (US)
Pages (from-to)	S28-S30
Journal	Journal of Investigative Dermatology Symposium Proceedings
Volume	20
Issue number	1
DOIs	https://doi.org/10.1016/j.jisp.2020.04.004
State	Published - Nov 2020

Bibliographical note

Publisher Copyright:
© 2020 The Author

Access

10.1016/j.jisp.2020.04.004

OpenUrl availability

Full text

Cite this

@article{d332c1f4a1e1433a9e75e62f58be86ff,

title = "Current Treatment of Alopecia Areata",

abstract = "The number of alopecia areata (AA) clinical trials with Jak inhibitors of cytoplasmic tyrosine kinases, including Jak1, Jak2, Jak3, and tyrosine-protein kinase has increased significantly since the last Research Summit. This fact means that the conversation about current treatments for AA now also needs to include a discussion of traditionally used off-label therapies as well as evolving therapies as with Jak inhibitors.",

author = "Hordinsky, {Maria K.}",

note = "Publisher Copyright: {\textcopyright} 2020 The Author",

year = "2020",

month = nov,

doi = "10.1016/j.jisp.2020.04.004",

language = "English (US)",

volume = "20",

pages = "S28--S30",

journal = "Journal of Investigative Dermatology Symposium Proceedings",

issn = "1087-0024",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Current Treatment of Alopecia Areata

AU - Hordinsky, Maria K.

PY - 2020/11

Y1 - 2020/11

N2 - The number of alopecia areata (AA) clinical trials with Jak inhibitors of cytoplasmic tyrosine kinases, including Jak1, Jak2, Jak3, and tyrosine-protein kinase has increased significantly since the last Research Summit. This fact means that the conversation about current treatments for AA now also needs to include a discussion of traditionally used off-label therapies as well as evolving therapies as with Jak inhibitors.

AB - The number of alopecia areata (AA) clinical trials with Jak inhibitors of cytoplasmic tyrosine kinases, including Jak1, Jak2, Jak3, and tyrosine-protein kinase has increased significantly since the last Research Summit. This fact means that the conversation about current treatments for AA now also needs to include a discussion of traditionally used off-label therapies as well as evolving therapies as with Jak inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85092446913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092446913&partnerID=8YFLogxK

U2 - 10.1016/j.jisp.2020.04.004

DO - 10.1016/j.jisp.2020.04.004

M3 - Comment/debate

C2 - 33099380

AN - SCOPUS:85092446913

SN - 1087-0024

VL - 20

SP - S28-S30

JO - Journal of Investigative Dermatology Symposium Proceedings

JF - Journal of Investigative Dermatology Symposium Proceedings

IS - 1

ER -

Current Treatment of Alopecia Areata

Abstract

Bibliographical note

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this